Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $67.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 149.91% from […]
More Stories
CleanSpark (NASDAQ:CLSK) Shares Down 4.4% – Here’s Why
CleanSpark, Inc. (NASDAQ:CLSK – Get Free Report)’s stock price fell 4.4% during trading on Tuesday . The stock traded as...
NIO (NYSE:NIO) Trading Down 2.5% – What’s Next?
Nio Inc – (NYSE:NIO – Get Free Report) was down 2.5% during mid-day trading on Tuesday . The company traded...
UnitedHealth Group (NYSE:UNH) Shares Up 0.1% – Still a Buy?
UnitedHealth Group Incorporated (NYSE:UNH – Get Free Report) shares rose 0.1% on Tuesday . The company traded as high as...
Birch Capital Management LLC Has $566,000 Stake in Antero Midstream Co. (NYSE:AM)
Birch Capital Management LLC increased its position in Antero Midstream Co. (NYSE:AM – Free Report) by 1.8% during the fourth...
JPMorgan Chase & Co. Cuts Webster Financial (NYSE:WBS) Price Target to $65.00
Webster Financial (NYSE:WBS – Get Free Report) had its price target reduced by equities researchers at JPMorgan Chase & Co....
Chevron (NYSE:CVX) Trading Up 1.8% – Should You Buy?
Chevron Co. (NYSE:CVX – Get Free Report) was up 1.8% during mid-day trading on Tuesday . The company traded as...